Navigation Links
Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce Distribution Agreement
Date:1/20/2013

TURKU, Finland and LIMERICK, Ireland, January 21, 2013 /PRNewswire/ --

BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement. Under the agreement, Olympus Biotech International will have exclusive distribution rights for the BonAlive® granules product line in Germany, France and the UK. The product line covers regenerative products for orthopaedic and trauma surgeries.

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-a)

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-b)

The agreement is an important milestone in the commercialization strategy of the BonAlive® granules product line in the pathway of further expanding the access to hospitals in the large European markets.

"This newly established partnership enables us to work together with one of the most prominent leaders in the field of regenerative medicine in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons" said Dr. Fredrik Ollila , CEO of BonAlive Biomaterials Ltd. "The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone".

"The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone regeneration portfolio now also in the treatment of fractures and non-unions in patients with chronic infections. During our thorough global
'/>"/>

SOURCE BonAlive Biomaterials Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Olympus Introduces the Worlds First and Only Monopolar, Disposable Tonsil Adenoid Debrider (DTAD)
2. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
3. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
4. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
5. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
6. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
7. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
8. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
9. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
10. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
11. Lifeline Biotechnologies Receives Third Software Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... Patent Covers Compositions and Methods, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... of U.S. Patent No. 7,371,741 covering analogs of ... of use intellectual property protection through 2025 for ...
... BASEL, Switzerland, June 11 , - Data ... That,NeoRecormon use has no Negative Impact on Overall ... all 12 prospective, randomised, controlled,studies in 2,301 cancer ... has no negative impact on survival, tumour,progression or ...
Cached Medicine Technology:EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 3New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients 2
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Measures taken by Firestone officials ... Liberia may have limited the spread of the disease ... The Firestone Natural Rubber Co. provides health services to ... nearby densely populated communities. Between Aug. 1 and ... cases among those 80,000 people. That incidence rate of ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts ... facts, figures and forecasts on the global medical markets. ... categories the Worldwide Medical Market Forecasts to 2019 ... on the worldwide medical market to reveal key insights ... data for 2010-2019, covering each country market individually, allowing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... Cornell University in the United States used rich microdata ... to analyze the correlation between high school completion and ... and obesity. Their findings, which are to be ... Journal of Labor Economics, reveal that, high ...
... cloned a cow with genes resistant to mad cow disease. ... a 55-kg calf //in the eastern province of Shandong ... to have used gene-transplant technology to introduce the genes to ... ,The lead researchers were Dong Yajuan and Bo Xuejin ...
... role in regulating cell death, a Queen’s University study has ... may be used to promote cell death in cancer cells ... as in neuronal cells in the case of Alzheimer’s or ... Molecular Medicine with the Cancer Biology and Genetics division of ...
... implemented by government are needed to improve mental health in ... Australia is in need of a new nationalwise approach with ... ,A report on the Time for Service says mental health ... following 5 years was being made. ,It added, ...
... Center have successfully accomplished the removal of an extremely rare, ... ,They removed one of his two left arms that ... left arm is further up his shoulder. ,‘We ... formed just as they would be for a normal arm,’ ...
... out human-to-human transmission of bird flu in the case ... // , easing fears that the virus might be ... ,'The negative test results for all four nurses ... efficiently or sustainably among humans at present,' WHO said ...
Cached Medicine News:Health News:Protein’s role in regulating cell death sets direction for Alzheimer’s, Parkinson’s and cancer resea 2
... Farnsworth Dichotomous testing sets are designed to ... Farnsworth D15 test is used to separate ... The L'Anthony Desaturated test is much more ... deficiency from Normal. Both of these ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Single Use Loading Units with Titanium Staples for use with Powered MULTIFIRE ENDO GIA™ 60 (15 mm Single Use Stapler with Titanium Staples)....
Medicine Products: